Home

Dr. Vuong Trieu/ CEO is to present at 11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research: Biology to Precision Medicine, February 8 – 12, 2019, Maui, Hawaii, USA. The presentations are as follow: D29/ Clinical efficacy of OT-101: A TGF-β2 antisense and proposed confirmatory phase 2/3 trial in Pancreatic Cancer (PC)/ Tuesday, 2/12/2019 and B71/Clinical efficacy of OT-101 a TGF-β2 antisense and proposed confirmatory phase 2/3 trial in Glioblastoma/ Sunday, 2/10/2019

Click here for Glioma poster  >>

Click here for Pancreas Cancer poster  >>

Dr. Larn Hwang PhD/ CSO to present at ASCO-SITC on February 28 – March 2, 2019 in the San Francisco Marriott Marquis, California.

Click here for more information  >>

Dr. Vuong Trieu, CEO, will be presenting the clinical study results titled “Non-inferiority of OT-101 (TGF-β2 Specific Inhibitor) versus Standard Chemotherapy in Glioma” on September 24th & 25th, 2018 at the 2018 American College of Clinical Pharmacology (ACCP) Annual Meeting in Bethesda, Maryland.

Click here for the poster in PDF  >>